Purchase Order HHSN271201700007A

Award Date 5/12/17
Potential Completion Date 5/25/22
Potential Value $697K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cape Fear, NC 28401, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $3,358,776 cost-plus-fixed-fee Delivery Order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO). The award is for a Phase I randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of a medical product. The contract is a task order under NIDA's "Phase I Clinical Trials for Development of Neurotherapeutics" Indefinite...
This is a $3,265,588.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), to PPD Development LP, a global contract research organization. The contract is for a first-in-human randomized, double-blind, placebo-controlled single ascending dose (SAD) Phase I study on the development of neurotherapeutics. The contract is not set aside and is...
This is a $324,420.00 firm fixed-price delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO). The contract is for research and development services related to clinical studies in the Blueprint MedTech program, including clinical study protocol development. The contract has a 5-year period of performance from June 17, 2024 to June 16, 2029, with a base period and two option units. PPD...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $500,263.64 Delivery Order contract to PPD Development LP, a global contract research organization (CRO), for clinical site and study monitoring services in support of research partnerships for global mental health. The contract has a period of performance from September 28, 2018 to September 27, 2023 and is a labor hours type contract. PPD Development LP has provided over $500...
This federal contract award is for regulatory consulting assistance and research and development for clinical studies in the Blueprint MedTech program, which is managed by the National Institute on Drug Abuse (NIDA), a civilian agency. The award was made to PPD Development LP, a global contract research organization (CRO) and subsidiary of Thermo Fisher Scientific. The contract has a period of performance from September 15, 2023 to September 14, 2024, with a ceiling value of $64,107.00. This...
This is a $1,737,262.53 task order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke to PPD Development LP, a global contract research organization (CRO). The task order is for Phase I clinical trials in the development of neurotherapeutics and is part of the larger "Phase I Clinical Trials for Development of Neurotherapeutics" indefinite delivery/indefinite quantity (ID/IQ) contract....
This is a $5,334 cost-plus-fixed-fee delivery order task order awarded to PPD Development LP, a global contract research organization (CRO), by the National Institute on Drug Abuse (NIDA). The task order is for the preparation of pre-submission support for a pilot participant under the Blueprint MedTech (BPMT) program, which provides CRO support for regulatory affairs. The award has an ultimate completion date of December 19, 2025, and there is no set-aside designation. PPD Development LP, a...
This is a cost-plus-fixed-fee definitive contract awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to PPD Development LP, a global contract research organization (CRO), for R&D services related to biomedical basic research. The $27,437,431.92 contract has a performance period ending on October 31, 2021 and is not set aside for any specific business type. PPD Development LP has been awarded over $500 million in prime federal...
This is a Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to PPD Development LP for NIAID Clinical Site Monitoring services. The contract has a ceiling value of $140,719,763.00 and a period of performance ending on January 31, 2024. PPD Development LP is a global contract research organization (CRO) that provides clinical trial and research support services to federal...
This is a Cost Plus Fixed Fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to PPD Development LP, a global contract research organization (CRO). The contract, valued at $66,339,562.95, is for the TAS::75 0885::TAS NIAID DAIT CLINICAL SITE MONITORING CENTER and has a performance period ending on February 23, 2023. PPD Development LP, a subsidiary of Thermo Fisher...

This is a firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The contract, valued at $696,693.16, was awarded to PPD Development LP, a global contract research organization (CRO), to provide PPD development site and study monitoring services. The contract has no set-aside designation and is part of several indefinite delivery contracts (IDCs) that PPD holds with NIDA, the National Cancer Institute (NCI), and the Defense Health Agency to support a wide range of clinical research and development initiatives, including those focused on infectious diseases, neurological disorders, substance use disorders, and medical device innovation. This contract is part of NIDA's portfolio of research programs and studies.

Generated 6/25/24, 1:12 PM